Not Yet RecruitingNot Applicable

International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

Italy361 participantsStarted 2026-02

Plain-language summary

The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged \>18years * Histologically confirmed diagnosis of la/mUC of upper and/or lower urinary tract or histologically confirmed diagnosis of rare GU tumors. * Histologically or radiologically confirmed metastatic disease * Patients treated with first-line EV+P combination Exclusion Criteria: * Patients without histologically confirmed diagnosis of UC * Patients without histologically or radiologically confirmed la or mUC

What they're measuring

overall survival in patients with la/mUC or rare GU tumors

Timeframe: December 2030

progression-free survival

Timeframe: December 2030

Trial details

NCT IDNCT07420855

SponsorAron Research Foundation Ets

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11

Contact for this trial

Matteo Santoni, Medical Doctor

+39 matteo.santoni82@gmail.com

View on ClinicalTrials.gov More Locally Advanced or Metastatic Urothelial Cancer trials